CurEzima

This invention relates to a pharmaceutical composition comprising ezetimibe, alone or in combination with curcumin, for the treatment of cancers characterised by the overexpression of the oncogene Mdm2. The technology is based on the novel discovery that ezetimibe, an FDA-approved cholesterol absorption inhibitor, can bind to the p53-binding domain of Mdm2, thereby promoting p53 tumour-suppressing activity and inducing apoptosis of cancer cells. The co-administration with curcumin further enhances therapeutic efficacy, particularly in colon cancer, by inhibiting ezetimibe’s glucuronidation and prolonging its bioavailability in the target tissues.